Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. has demonstrated strong financial momentum, highlighted by Integrity achieving sequential revenue growth and a projected over 100% increase in 2025 revenue compared to 2024. The company's international osteoarthritis (OA) pain revenue reflected a robust 21% growth year-over-year, indicating expanding market acceptance of its products outside the U.S. Additionally, the regenerative solutions segment experienced impressive growth of 41% in Q1, significantly propelled by the Integrity patch, showcasing a solid performance across its therapeutic offerings.

Bears say

Anika Therapeutics, Inc. has reported a decline in revenue, generating $27.8 million, which marks a 5.9% decrease compared to the previous year, excluding recent divestitures, highlighting persistent challenges in revenue generation. The company also faced disappointing gross margins of 56%, falling short of the estimated 58%, primarily due to ongoing production yield issues that have negatively impacted operational efficiency. Additionally, the international revenue from osteoarthritis pain management declined by 10% compared to the same quarter last year, further emphasizing the company's struggles in maintaining stable growth in an already challenging market environment.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.